Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China

Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China

BackgroundProgrammed cell death-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors are increasingly used in China, but no real-world data are available about the immune-related adverse events (irAEs). This real-world retrospective study aimed to assess the safety and effectiveness of PD-1/PD-L...

Full description

Bibliographic Details
Main Authors: Xiaoling Chen, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Jindi Han, Xiangjuan Ma, Guangming Tian, Sen Han, Di Wu, Yang Wang, Jieran Long, Ziran Zhang, Jian Fang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-03-01
Series:Frontiers in Oncology
Subjects:
non-small cell lung cancer
immunotherapy
adverse events
real-world evidence
objective response
survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.607531/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.607531/full

Similar Items